CI Cherkasy Regional Oncological Dispensary of CRC

Cherkasy 18009

0 studies enrolling now · 1 studies all time

What they study most

Chemotherapeutic Toxicity, Colorectal Cancer Metastatic, Myelosuppression-Adult

Studies at this site

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): — Stopped early